Optimizing Induction Therapy for Newly Diagnosed Multiple Myeloma: Navigating the Treatment Options
Release Date: October 14, 2019
Expiration Date: October 14, 2020
Expected time to complete this activity as designed: 30 minutes
There are no fees for participating in or receiving credit for this online activity.
Managing a newly diagnosed patient with multiple myeloma can present challenges. In this activity, Dr. Nooka covers the key aspects of management including the predictive measures currently available for risk stratification in newly diagnosed multiple myeloma (NDMM). He will also discuss the key clinical- and patient-related factors that could influence your choice of induction regimen, the safety and efficacy of the current modern day induction regimens in the frontline setting, as well as the role of monoclonal antibodies and the treatment of newly diagnosed myeloma patients in frontline setting.
This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, pharmacists and other allied healthcare professionals who provide care to patients with newly diagnosed multiple myeloma.
Upon completion of this educational activity, participants should be able to:
- Describe predictive measures available for determining risk stratification and patient-centered management in newly diagnosed multiple myeloma
- Outline key clinical- and patient-related factors which may influence your selection of induction therapy for newly diagnosed multiple myeloma patients who are eligible or ineligible for transplant
- Evaluate safety and efficacy of current emerging multi-drug combinations used in the frontline setting
- Identify the potential impact of monoclonal antibodies on the treatment paradigm for newly diagnosed multiple myeloma
Optimizing Induction Therapy for Newly Diagnosed Multiple Myeloma: Navigating the Treatment Options – Ajay K. Nooka, MD, MPH, FACP
Instructions for Participation and Credit
This activity is eligible for credit through October 14, 2020. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME credit may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Ajay K. Nooka, MD, MPH, FACP
Department of Hematology and Medical Oncology
Winship Cancer Institute
Emory University School of Medicine
Dr. Ajay Nooka received his medical degree from Andhra Medical College in India before relocating to the United States. He received a master’s in public health from The University of Texas School of Public Health in Houston, and then completed his internship and residency at the Northeastern Ohio University College of Medicine. He also pursued a fellowship in hematology and oncology at Emory University School of Medicine in Atlanta, Georgia where he also served as chief fellow before he joined the faculty. Dr. Nooka is currently an Associate Professor in the Department of Hematology and Medical Oncology at the Winship Cancer Institute of Emory University.
Board certified in hematology and medical oncology, Dr. Nooka primarily focuses on multiple myeloma treatment and research. He is involved in numerous professional organizations, including the American Society of Clinical Oncology, the American Society of Hematology, and the American Society for Blood and Marrow Transplantation.
Dr. Nooka’s interests as a clinical investigator focus on multiple myeloma and bone marrow transplant. His research interests include integrating genomic and clinical data on a uniform platform to risk-stratify myeloma, and to evaluate newer myeloma therapeutic strategies aimed at prolonging survival in myeloma patients. In addition to leading several investigator-initiated and industry-sponsored clinical trials, he is a recipient of several awards and grants including the Multiple Myeloma Research Foundation Accelerator Award and the International Myeloma Foundation Research Grants. He has published more than 200 articles and abstracts in peer-reviewed journals including The New England Journal of Medicine, Journal of Clinical Oncology, Blood, Leukemia, Lancet Oncology, and Cancer. In addition, he serves on the editorial board of the American Journal of Clinical Oncology and as an invited/ad hoc reviewer for several prestigious journals including Lancet Oncology, Journal of Clinical Oncology, Cancer, Bone Marrow Transplantation, and Biology of Blood and Marrow Transplantation.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.5 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-19-025-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Ajay Nooka has received honoraria related to formal advisory activities from Amgen Inc., Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Spectrum Pharmaceuticals, Inc., Oncopeptides, AB, and Takeda Oncology. He has received grant support related to research activities from Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, and Takeda.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Andrea Mathis, Project Manager, Joan Meyer, RN, MHA, Executive Director, and Bill Stoff, Director of Operations, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at firstname.lastname@example.org
Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation.
©2019 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.